Ali Raif Pharmaceuticals Tops Trademark Filings from Its R&D Center
Results have been announced for Türkiye’s Top 250 Companies with the highest R&D spending. Turkishtime’s 2023 R&D 250 Research has ranked Ali Raif İlaç ranked first in the number of trademarks secured at its R&D Center.
Turkishtime’s 11th annual cross-sector report on Turkish industry draws from official data and disclosures by companies with R&D centers certified by the Ministry of Industry and Technology, as part of the R&D 250 Study. The study evaluates companies based on 2023 R&D spending, 2024 R&D budgets, R&D staff counts, and patents, utility models, design registrations, and trademarks generated by their R&D Centers in 2023.
Ali Raif Pharmaceuticals ranked among Türkiye’s top 250 R&D spenders in 2023, leading the way with 111 trademarks filed from its R&D Center.
Ali Raif Pharmaceuticals, a pillar of Türkiye’s pharmaceutical sector with 60 years of expertise and 100% domestic capital, has established its prominence through unwavering dedication to enhancing life quality and advancing public health. Boasting a diverse portfolio with 240+ different pharmaceutical products across 90+ brands, the company continually invests in innovation, reinforcing its mission to elevate healthcare standards. Supported by a team that believes in science and understands the impact of research, Ali Raif Pharmaceuticals will continue to advance its efforts at the R&D Center, bringing innovative products to the Turkish pharmaceutical industry.
